MULTICHANNEL BIOPRINTER FOR MEDICAL DIAGNOSTICS

我们将建立一个“生物芯片”，用于快速鉴定分枝杆菌， 临床标本生物芯片将具有50-100个寡核苷酸探针 点在1.8厘米（2）阵列。探针将揭示（i）哪种分枝杆菌 DNA存在于患者的标本中，以及（如果结核分枝杆菌）（ii）确切地说， 存在结核分枝杆菌突变体。针对患者的抗菌治疗 因此，所鉴定的分枝杆菌的易感性可以在 样本接收时间。 MicroFab将建造“生物打印机”，用于在生物芯片上打印DNA探针。 样品制备、DNA扩增方案和选择 将从现在的协议中开发探针集， 临床/实验应用贝勒的道和马瑟 结核病中心。光学、数据处理和信息学 将开发用于成像和“阅读”芯片的系统 MicroFab和合作者 结核分枝杆菌每秒钟感染一个病人，杀死的人比其他任何人都多。 传染病快速进化的耐药菌株使得 基因分型是及时有效治疗的必要条件我们的生物芯片将 成本不超过5.00美元的数量，确保广泛供应。 此外，我们的生物打印机将很容易适应cDNA生物芯片， 患者对HIV的治疗反应的个体化表型， 癌症和其他多种疾病。 拟议的商业应用： M.肺结核是传染病中的头号杀手 国际吧快速、廉价的结核病诊断和鉴定可以 大大减少了传播。更一般地，生物打印机能够 生产微观尺寸和高密度的免疫和DNA探针阵列 整个生物医学和生物技术领域都需要大量的信息。系统我们 很容易成为最先进的阵列制造技术 所有诊断产品。

We will build a "BioChip" for rapid identification of mycobacteria in clinical specimens. The BioChip will have 50-100 oligonucleotide probe spots in a 1.8 cm(2) array. Probes will reveal (i) which mycobacterial DNA are present in a patient's specimen, and (if M.tb) (ii) exactly which M.tb mutant(s) are present. Antimicrobial therapy tailored to the susceptibility of the identified mycobacterium can thus commence within hours of specimen receipt. MicroFab will build the "BioPrinter" for printing DNA probes on BioChips. The sample preparation, DNA amplification protocols, and the selection of the probe set will be developed from the protocols now in clinical/experimental use by Dr.'s Dao and Musser in the Baylor Tuberculosis Center. The optical, data-processing, and informatics systems to be used for imaging and "reading" the chip will be developed by MicroFab and collaborators. M.tb infects 1 patient per second, and kills more people than any other infectious disease. Rapidly evolving drug-resistant strains make genotyping mandatory for a prompt, effective therapy. Our BioChips will cost no more than $5.00 in quantity, assuring widespread availability. Moreover, our BioPrinter will be readily adaptable to cDNA BioChips for individualized phenotyping of patient's therapeutic responses to HIV, cancer, and other multifaceted diseases. PROPOSED COMMERCIAL APPLICATIONS: M. tuberculosis is the number one killer among infectious diseases worldwide. Fast, inexpensive diagnosis and identification of Mtb can dramatically reduce the spread. More generally, a BioPrinter capable of producing immuno- and DNA-probe arrays in microscopic size and high volume is needed throughout biomedicine and biotechnology. The system we are developing could easily become the premier array-making technology for all diagnostic production.